Organ-specific or personalized treatment for COVID-19: rationale, evidence, and potential candidates

Mousavi, Seyedeh Zahra; Rahmanian, Mojdeh; Sami, Ashkan

Abstract

Although extrapulmonary manifestations of coronavirus disease 2019 (COVID-19) are increasingly reported, no effective therapeutic strategy for these multisystemic complications is available due to a poor understanding of the pathophysiology of COVID-19 multiorgan involvement. In this study, differentially expressed genes (DEGs) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected extrapulmonary organs including human pluripotent stem cells (hPSCs)-derived liver organoids and choroid plexus organoids besides transformed lung alveolar (A549) cells were analyzed. First, pathway enrichment analysis was done to compare the underlying biological pathways enriched upon SARS-CoV-2 infection in different organs. Then, these lists of DEGs were used in a connectivity map (CMap)-based drug repurposing experiment. Also, protein–protein interaction (PPI) network analysis was done to compare the associated hub genes. The results revealed different biological pathways and genes responsible for SARS-CoV-2 multisystemic pathogenesis based on the organ involved that highlighted the need for considering organ-specific treatments or even personalized therapy. Besides, some FDA-approved drugs were proposed as the potential therapeutic candidates for each infected cell line.

Citation

Mousavi, S. Z., Rahmanian, M., & Sami, A. (2022). Organ-specific or personalized treatment for COVID-19: rationale, evidence, and potential candidates. Functional and Integrative Genomics, 22(3), 429-433. https://doi.org/10.1007/s10142-022-00841-z

• Journal Article Type: Article
• Acceptance Date: Mar 8, 2022
• Online Publication Date: Mar 15, 2022
• Publication Date: 2022-06
• Deposit Date: Jul 15, 2024
• Print ISSN: 1438-793X
• Electronic ISSN: 1438-7948
• Publisher: Springer
• Peer Reviewed: Peer Reviewed
• Volume: 22
• Issue: 3
• Pages: 429-433
• DOI: https://doi.org/10.1007/s10142-022-00841-z
• Keywords: COVID-19; SARS-CoV-2; Organ-specific treatment; Personalized medicine; Drug repurposing
• PMID: 35290538